JADE BIOSCIENCES INC
JBIONASDAQ🏆 #1712 by market capEarnings Aug 11 · PreUS Equity
$22.34▲ $0.61 (+2.74%)
Live1h—
24h▲ 2.7%
7d▲ 4.7%
14d▲ 13.4%
30d▲ 6.8%
1y▲ 202.2%
🏦Market Cap
$1.36B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
55
Weak
Trading Snapshot
- Day Range
- $22.14 – $22.44
- 52-Week Range
- $6.67 – $28.00
- Volume
- $3.22B
- Avg Volume
- $2.23B
- Shares Outstanding
- 60.9M
- Next Earnings
- Oct 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $234M
- Last Q Revenue
- $53M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.06
- Dividend Yield
- —
Why Investors Own JBIO
- ✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 73% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$234M▲ +24.1% YoY
Gross Margin (TTM)
73.0%▲ +4.0% YoY
Operating Income (TTM)
$65M▲ +24.1% YoY
Free Cash Flow (TTM)
$57M▲ +24.1% YoY
About JADE BIOSCIENCES INC
A company profile for JADE BIOSCIENCES INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
55/100
Analyst Price Target
ⓘAverage Target
$26.83
▲ +20.1% Upside
High Target$30.22
Low Target$22.29
Based on 36 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
JADE BIOSCIENCES INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift JBIO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
JADE BIOSCIENCES INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.